Normocomplementemic urticarial vasculitis: effective treatment with omalizumab

Authors

  • Ana Laura Costa José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina
  • Antonella Cilio José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina
  • Sabrina Merenzon José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina
  • Lola Kuperman Wilder José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina
  • Luciana Cabral Campana José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina
  • Gabriela Bendjuia José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v31i3.2960

Keywords:

normocomplementemic urticarial vasculitis, omalizumab, IgE

Abstract

Urticarial vasculitis is a small vessel cutaneous vasculitis that presents clinically with erythematous edematous plaques that persist for more than 24 hours, which may be associated with itching and burning, significantly affecting the quality of life of patients. Treatment is challenging since available therapies have limited efficacy. Omalizumab may be a promising option for its treatment. We present 3 cases of normocomplementemic urticarial vasculitis with good response to treatment.

Author Biographies

Ana Laura Costa, José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

Dermatologist, Dermatology Department

Antonella Cilio, José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

Dermatologist, Dermatology Department

Sabrina Merenzon, José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

Dermatologist, Dermatology Department

Lola Kuperman Wilder, José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

Dermatologist, Dermatology Department

Luciana Cabral Campana, José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

Dermatologist, "Autoimmune blistering diseases, stomatology and dermatology, and sexual diversity sector", Dermatology Service

Gabriela Bendjuia, José María Ramos Mejía General Acute Care Hospital, City of Buenos Aires, Argentina

Dermatologist, Collagen Diseases Section, Head of the Inpatient Unit, Dermatology Department

References

I. Kolkhir P, Grakhova M, Bonnekoh H, Krause K, et ál. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143:458-466.

II. Díez L, Tamayo LM, Cardona R. Omalizumab: opción terapéutica para la urticaria crónica espontánea de difícil control con vasculitis asociada, reporte de tres casos; Biomédica. 2013;33:503-512.

III. Morita TCAB, Criado PR, Criado RFJ, Trés GFS, et ál. Update on vasculitis: overview and relevant dermatological aspects for the and histopatological diagnosis. Part II. An Bras Dermatol. 2020;95:493-507.

IV. De Brito M, Huebner G, Murrell D, Bullpitt P, et ál. Normocomplementaemic urticarial vasculitis: efective treatment with omalizumab. Clin Transl Allergy. 2018;8:37.

V. Taoming L, Bai J, Ying S, Sheng L, et ál. Real-world experience on omalizumab treatment for patients with normocomplementemic urticarial vasculitis. J Asthma Allergy 2021;14:433-437.

VI. Ghazanfar MN, Thomsen SF. Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med. 2015;2015:576893.

VII. Degirmentepe EN , Kızıltac K , Etikan P , Singer R , et ál. Omalizumab as a succesfull therapy in normocomplementemic urticarial vasculitis. A series of four patients and review of the literature. Ann Dermatol. 2019;31:335-338.

Downloads

Published

2025-12-01

Issue

Vol. 31 No. 3 (2025): September-December

Section

Original Articles

License

Copyright (c) 2025 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor